News

Show
news from

Syncona Half Year Results for the Period Ending 30 September 2022

Freeline Reports Third Quarter 2022 Financial Results and Corporate Update

Anaveon presents updated data from the Phase I/II study of ANV419 during the SITC Annual Meeting

Publication in Nature Chemistry Demonstrates the Benefits of Native Mass Spectrometry in the Interrogation of Target Ecosystems and Drug Discovery

Resolution Therapeutics Announces the Appointment of Lisa Bright as Chair of its Board of Directors

Resolution Therapeutics and CCRM sign collaboration agreement to develop and scale up manufacturing for induced pluripotent stem cell (iPSC)-derived macrophage cell therapies

Load more

Search